Triclosan Antigingivitis Effectiveness Data Questioned By P&G, Colgate
This article was originally published in The Rose Sheet
Executive Summary
Data evaluating the efficacy of triclosan as an antigingivitis ingredient do not support its inclusion as a Category I active in the OTC Antigingivitis/ Antiplaque Monograph, according to the oral care industry's two leading marketers, Procter & Gamble and Colgate-Palmolive
You may also be interested in...
FDA Will Consider Triclosan For OTC Acne Monograph Inclusion
FDA is seeking data on use of triclosan in topical acne treatment products, the agency announced in a Dec. 5 Federal Register 1notice
FDA Will Consider Triclosan For OTC Acne Monograph Inclusion
FDA is seeking data on use of triclosan in topical acne treatment products, the agency announced in a Dec. 5 Federal Register 1notice
Ciba Triclosan Application Does Not Meet TEA Criteria, Colgate Argues
Triclosan should not be included as a Category I active in the antigingivitis OTC drug products monograph because data does not prove the ingredient meets the criteria for time and extent exclusion from FDA's definition of a new drug, Colgate-Palmolive maintains in Aug. 16 comments to the agency